Squarepoint Ops LLC Has $6.04 Million Stake in Alkermes plc $ALKS

Posted by George Bondi on Sep 12th, 2026

Squarepoint Ops LLC reduced its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 58.5% during the 2nd quarter, Holdings Channel reports. The fund owned 115,195 shares of the company’s stock after selling 162,424 shares during the quarter. Squarepoint Ops LLC’s holdings in Alkermes were worth $6,036,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of ALKS. Ameritas Advisory Services LLC acquired a new stake in Alkermes during the 2nd quarter valued at $39,000. Cullen Frost Bankers Inc. acquired a new position in Alkermes in the fourth quarter worth $28,000. Johnson Financial Group Inc. acquired a new position in Alkermes in the third quarter worth $31,000. UMB Bank n.a. grew its holdings in shares of Alkermes by 57.6% during the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock worth $34,000 after purchasing an additional 446 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of Alkermes by 1,041.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock worth $37,000 after purchasing an additional 1,208 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ALKS shares. Stifel Nicolaus restated a “buy” rating and issued a $63.00 target price (up from $45.00) on shares of Alkermes in a research note on Monday, July 20th. Piper Sandler reissued an “overweight” rating and set a $65.00 price objective (up from $43.00) on shares of Alkermes in a report on Tuesday, July 28th. Robert W. Baird raised their price objective on shares of Alkermes from $48.00 to $58.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. HC Wainwright restated a “neutral” rating on shares of Alkermes in a research report on Thursday, July 30th. Finally, Bank of America reaffirmed an “underperform” rating on shares of Alkermes in a research note on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $54.56.

Read Our Latest Stock Analysis on ALKS

Alkermes Stock Performance

Shares of NASDAQ:ALKS opened at $45.97 on Friday. The firm’s 50 day simple moving average is $49.82 and its 200 day simple moving average is $41.36. Alkermes plc has a fifty-two week low of $26.40 and a fifty-two week high of $55.67. The company has a market capitalization of $7.71 billion, a price-to-earnings ratio of 120.98 and a beta of 0.31. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.30 and a quick ratio of 1.85.

Insider Activity

In other Alkermes news, EVP David Gaffin sold 2,034 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $48.01, for a total value of $97,652.34. Following the sale, the executive vice president directly owned 223,422 shares in the company, valued at approximately $10,726,490.22. This trade represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $46.99, for a total transaction of $422,910.00. Following the transaction, the executive vice president directly owned 65,389 shares in the company, valued at approximately $3,072,629.11. This represents a 12.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 85,150 shares of company stock worth $4,242,213 over the last three months. Company insiders own 4.59% of the company’s stock.

Alkermes Profile

(Free Report)

Alkermes plc (NASDAQ: ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities include treatments for schizophrenia, bipolar disorder, addiction and other serious neurological or psychiatric conditions, with an emphasis on long-acting injectable and extended-release formulations.

The company’s marketed products include VIVITROL, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence after detoxification; ARISTADA, an extended-release injectable formulation of aripiprazole lauroxil for the treatment of schizophrenia in adults; and LYBALVI, an oral combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in Ireland in 1987, Alkermes has developed drug-delivery technologies intended to help extend dosing intervals and support medication adherence.